Deal in Focus · Merger and acquisition financing

Kimberly-Clark buys Kenvue

One shelf from two. The paper goods and the medicine-cabinet staples now belong to one company, and the work that follows is deciding how they sit together on the same shelf.

Kimberly-Clark paid for Kenvue mostly in its own shares, so what its holders gain turns on the disclosed synergies against the premium.

By Surojit Chakraverti, founder of L3VLUP and an investor running a long-short healthcare and technology equities strategy.

On this subject: the Kenvue Inc. case.Updated 20 November 2026

Completed on 2 November 2026 · Information to 5 November 2026

Each Kenvue share receivedOffer
$3.50 + 0.14625 shares
$21.01 at the announcement
Run-rate synergiesFiling
$2.1bn
Net of reinvestment
Accretion, FY2028EModel
10.5%
Dilutive without synergies
Left for Kimberly-Clark’s holdersModel
$2,561.0m
At an illustrative 10x on the synergies

In brief

On 3 November 2025 Kimberly-Clark agreed to buy Kenvue, the consumer health company spun out of Johnson & Johnson, for $3.50 in cash and 0.14625 of a Kimberly-Clark share for each Kenvue share: $21.01 at the previous close, about $48.7bn of enterprise value and 14.3 times Kenvue’s trailing adjusted EBITDA, or 8.8 times with $2.1bn of run-rate synergies. Kenvue’s holders were to own about 46% of the combined company. Both sets of shareholders approved the deal on 29 January 2026, and it was completed on 2 November 2026, with about 281.1 million new shares issued and about $6.7bn of cash paid, funded with $4.9bn of new notes, about $1.0bn of commercial paper and cash on hand.

Every figure on this page is a cell in the Kimberly-Clark and Kenvue merger model, built from the documents in Sources. Each carries a tag: what the offer or a filing gives, what this page assumes, and what the model works out.

The transaction

Kenvue was the consumer health business of Johnson & Johnson until its listing in 2023: over-the-counter medicines, skin care and essential health brands, $15.1bn of revenue in 2025. Kimberly-Clark makes nappies, tissue and personal care products, $16.4bn of revenue in 2025 after agreeing to put most of its international tissue business into a joint venture. Kimberly-Clark paid for Kenvue with a fixed 0.14625 of its own shares and $3.50 in cash for each Kenvue share, so more than four fifths of the price was paid in stock.

The negotiation ran through a fall in Kenvue’s shares. Kimberly-Clark’s first proposal, on 28 August 2025, offered 0.1475 of a share and $6.00, worth $24.99 that day. A week later reports linked prenatal use of acetaminophen, the active ingredient in Tylenol, with autism, and Kenvue’s shares fell from $20.54 to $14.37 by 31 October. The cash per share came down from $6.00 to $3.50; the share ratio barely moved.

The central question

In a deal paid mostly in shares, the buyer’s holders give away part of the combined company. Whether they come out ahead depends on two numbers the filings disclose, the synergies and their cost, and on one they cannot: what those synergies are worth once achieved, set against the premium paid. The new debt and Kenvue’s litigation are what could put that answer at risk.

The model answers as conditional scenarios. Where the filings give a figure it uses it and cites it: the terms, the share counts, the funding, both companies’ projections, the synergy projections and the preliminary purchase accounting. Where they do not, it uses a labelled assumption you can change: the multiple put on the synergies, a slower downside, the rates on new borrowing and any litigation amount you choose to test.

The offer, the funding and what Kenvue’s holders received

The base case at completion. Change the price or the costs in Explore.

Sources and uses at completion

Uses$6,726m$33,646mSources$33,646m$4,900m0$40,681m
  • Cash to Kenvue holders
  • Kimberly-Clark shares to Kenvue holders
  • Transaction costs
  • Kimberly-Clark shares issued
  • New senior notes
  • Commercial paper
  • Kimberly-Clark cash
Read as a table
Uses$mSources$m
Cash to Kenvue holders6726Kimberly-Clark shares issued33646
Kimberly-Clark shares to Kenvue holders33646New senior notes4900
Transaction costs309Commercial paper1000
Kimberly-Clark cash1135

What Kenvue’s holders gave up and received

Before: the equity at the offerAfter: the capital that replaces itKenvue shares at the reference price$27,616mCash received$6,726mKimberly-Clark shares received$33,646m
Read as a table
Before$mAfter$m
Kenvue shares at the reference price27616Cash received6726
Kimberly-Clark shares received33646

Swipe the picture sideways to see all of it.

What Kenvue’s holders received, and on which price

At Kimberly-Clark’s $119.71 close on 31 October 2025 the offer was worth $21.01 a Kenvue share: $3.50 of cash and $17.51 of stock. Measured against Kenvue’s close that day it was a 46.2% premium; against its 90-day average of $18.24 it was about 15%. Both are in the joint proxy, and the gap between them is the acetaminophen news. Neither price is wrong: the first is where Kenvue traded with the risk priced in, the second where it traded for most of the summer.

The exchange ratio was fixed, with no collar, so the value of the stock moved with Kimberly-Clark’s price until completion. At $100 a Kimberly-Clark share the same terms are worth $18.13 a Kenvue share. The joint proxy’s own pro forma, at $103.76, put the total consideration at $36.8bn. The price on the day of completion is not in the filings read here.

The proposals, from the Background of the Mergers (joint proxy, pp.63 to 72)
DateShares per Kenvue shareCashValue at the timeKenvue close
28 August 20250.1475$6.00$24.99$20.54
14 October 20250.1400$4.00$20.70$16.22
24 October 20250.1450$4.00$21.22$15.09
31 October 20250.1450$3.00$20.36$14.37
31 October 2025, agreed0.14625$3.50$21.01$14.37

How the cash was paid for

The cash came to about $6.7bn on 1,921.8 million Kenvue shares. A $7.7bn bridge loan from JPMorgan Chase Bank secured it at signing; by completion it had been replaced with $4.9bn of senior notes at coupons from 5.100% to 5.800%, about $1.0bn of commercial paper and Kimberly-Clark’s own cash, which the joint venture for its international tissue business had topped up in July. Kenvue’s $7.0bn of notes were largely exchanged for Kimberly-Clark notes rather than repaid.

On the September 2026 balance sheets, combined debt at completion was about $20.6bn and net debt about $18.8bn, 2.5 times the two companies’ FY2027E EBITDA before synergies. Kimberly-Clark said it would bring net leverage to about 2.0 times within 24 months. On both companies’ projections, the disclosed synergies and a dividend held at $5.12 a share, the base case gets there in FY2028E, mostly because EBITDA grows: the dividend on the enlarged share count takes most of the free cash flow in the first two years, while the cost to achieve is spent.

How much of the earnings case rests on the synergies

Kenvue’s earnings do not pay for the shares issued for them. On Kimberly-Clark management’s view of Kenvue, the 281 million new shares take more from Kimberly-Clark’s standalone earnings per share than Kenvue’s profits add, and the interest on the funding and the amortisation of the acquired brands take more again. Without synergies the base case dilutes earnings per share by about 14% in FY2027E and about 15% in FY2028E.

The synergies turn that round. With the disclosed profile, 40% of the cost synergies in the first year and 80% in the second, earnings per share are roughly unchanged in FY2027E and about 10.5% higher in FY2028E, which is consistent with the announcement’s statement that the deal would add to adjusted earnings per share by its second year. In FY2028E the synergies supply about a quarter of pro forma earnings per share. Half of them, a year late, leaves the deal dilutive through FY2029E.

What the premium leaves for Kimberly-Clark’s holders

Accretion is not value. Put a multiple on the synergies and the question becomes whether they are worth more than the premium. At an illustrative 10 times the $2.1bn run-rate, less the $2.5bn of cost to achieve after tax, the $1.4bn of integration capital and the transaction costs, the synergies are worth about $17.5bn. The premium over Kenvue’s 31 October price was about $12.8bn, so roughly 73% of the synergy value was paid away before completion.

What is left, about $4.7bn, belongs to both sets of holders through the combined shares: Kimberly-Clark’s about $2.6bn and Kenvue’s about $2.2bn on top of the premium. Below about 7.8 times the synergies, Kimberly-Clark’s holders keep nothing. Measured against Kenvue’s 90-day average instead, the premium is about $5.3bn and far more is left. Kimberly-Clark’s own adviser PJT Partners valued Kenvue at $18.00 to $27.50 a share by discounted cash flow without synergies and $29.50 to $45.00 with them, against the $21.01 offered (joint proxy, p.94).

The litigation Kenvue brings, read from the filings

The filings describe the claims without sizing them. The federal acetaminophen cases ended in judgment for Kenvue’s subsidiary in 2024; in July 2026 the Second Circuit vacated that judgment in part and sent the cases back. Texas sued in October 2025, and part of that case was dismissed and is under appeal. Talc claims in the United States and Canada stay with Johnson & Johnson, which indemnifies Kenvue; claims elsewhere, in England, Scotland and Australia, stay with Kenvue. For each, Kenvue says it cannot reasonably estimate the likelihood or size of any liability.

The merger agreement put the acetaminophen risk on Kimberly-Clark from signing: developments relating to the autism and ADHD allegations could not count as a material adverse effect. Kimberly-Clark’s board listed it among the risks it weighed. The model carries no estimate of any outcome. It offers one control, nil by default, for an amount you want to test, paid in FY2027E and funded with debt: about $4.7bn would use up everything the base case leaves beyond the premium, a figure for scale and nothing more.

What is disclosed, and what is assumed

Filing From the documents

  • $3.50 in cash and 0.14625 of a Kimberly-Clark share for each Kenvue share, and the prices the announcement used
  • The shares at signing and the 281.1 million delivered at completion
  • The $4.9bn of notes, about $1.0bn of commercial paper and both balance sheets
  • Both companies’ projections to 2030, Kenvue’s in two versions
  • The synergy projections, their cost to achieve and the 2.0x leverage target
  • The preliminary purchase accounting and the litigation as Kenvue describes it

Assumption Illustrative, and yours to change

  • The multiple put on the synergies (10x) and the downside case
  • Rates on commercial paper and on later changes in net debt
  • Depreciation, interest and tax held at their 2025 levels
  • The dividend held at $5.12 and the timing of integration capital
  • Any litigation amount, nil unless you set one

No actual return for any party exists in the public record. The documents, the facts by source and what they leave out are in Sources.

Take the model into Excel

The workbook downloads with every input at the base case, the Sources sheet citing each disclosed figure, so what you change on the page you change again in Excel.

Download

Kimberly-Clark and Kenvue merger model: the workbook

An Excel workbook with working formulas, no macros and no external links: the same model you can work with on this page.

  1. Browse without an accountPreview every model online, sheet by sheet, with its outputs and checks.
  2. Free accountWork with every model online: change the inputs, switch the case, see every formula. And every starter workbook, with its key schedules left blank to build.
  3. L3VLUP Plus$4.99/monthEverything in Free, and one worked model each billing month as an Excel file: every schedule built, formulas live, checks at zero, yours to keep.
  4. L3VLUP Pro$25/monthEverything in Plus, every worked model in the library, and the Pro applications.
The worked model
11 sheets and 355 live formulas, all 10 schedules built and linked, every check reading zero. Change an input in Excel and the whole model moves.
The starter
The same inputs and layout with the pro forma EPS: accretion and dilution left blank for you to build, each blank cell marked. The worked model is its answer.

The method behind the case

Share your result 📊

𝕏in💬🤖

Instagram and TikTok have no desktop share link, so copy the caption and paste it into the app.